Ali H Hassan1, Khaled M Hosny2,3, Zuahir A Murshid1, Adel Alhadlaq4, Ahmed Yamani5, Ghada Naguib6, Hala M Alkhalidi7, Ahmed R Afify1. 1. a Department of Orthodontics , Faculty of Dentistry, King Abdulaziz University , Jeddah , Saudi Arabia . 2. b Department of Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, King Abdulaziz University , Jeddah , Saudi Arabia . 3. c Department of Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Beni Suef University , Beni Suef , Egypt . 4. d Department of Pediatric Dentistry and Orthodontics , Collage of Dentistry, King Saud University , Riyadh , Saudi Arabia . 5. e Department of Oral Surgery and. 6. f Department of Restorative Dentistry , Faculty of Dentistry, King Abdulaziz University , Jeddah , Saudi Arabia , and. 7. g Department of Clinical Pharmacy , Faculty of Pharmacy, King Abdulaziz University , Jeddah , Saudi Arabia.
Abstract
BACKGROUND AND OBJECTIVE: The aim of the present study was to develop and examine a new non-invasive injectable graft for the repair of alveolar bone clefts using recombinant human bone morphogenetic protein-2 (rhBMP-2) encapsulated within injectable liposomal in situ gel (LIG). METHOD: Different liposomal formulations loaded with rhBMP-2 were prepared, and the effects of the preparation methods and lipid content on the efficiency of rhBMP-2 encapsulation within the liposomes were studied. For the preparation of in situ gel, deacetylated gellan gum (DGG) was used, and the in vitro gelation characteristics of the gel were evaluated. In vivo pharmacokinetics and histology were also assessed. Critical size alveolar defects were surgically created in the maxillae of 30 New Zealand rabbits and treated with different injectable formulae, including rhBMP-2 liposomes and in situ gel (rhBMP-2-LIG). RESULTS: The results indicated that the prepared rhBMP-2-LIG prolonged the release and residence time of BMP-2 within rabbits for more than 7 days. Histomorphometric assessment showed 67% trabecular bone filling of the defects treated using this novel formula. CONCLUSION: BMP-2-LIG is a promising delivery device for the repair of alveolar bone defects associated with cleft deformities.
BACKGROUND AND OBJECTIVE: The aim of the present study was to develop and examine a new non-invasive injectable graft for the repair of alveolar bone clefts using recombinant humanbone morphogenetic protein-2 (rhBMP-2) encapsulated within injectable liposomal in situ gel (LIG). METHOD: Different liposomal formulations loaded with rhBMP-2 were prepared, and the effects of the preparation methods and lipid content on the efficiency of rhBMP-2 encapsulation within the liposomes were studied. For the preparation of in situ gel, deacetylated gellan gum (DGG) was used, and the in vitro gelation characteristics of the gel were evaluated. In vivo pharmacokinetics and histology were also assessed. Critical size alveolar defects were surgically created in the maxillae of 30 New Zealand rabbits and treated with different injectable formulae, including rhBMP-2 liposomes and in situ gel (rhBMP-2-LIG). RESULTS: The results indicated that the prepared rhBMP-2-LIG prolonged the release and residence time of BMP-2 within rabbits for more than 7 days. Histomorphometric assessment showed 67% trabecular bone filling of the defects treated using this novel formula. CONCLUSION:BMP-2-LIG is a promising delivery device for the repair of alveolar bone defects associated with cleft deformities.
Entities:
Keywords:
Alveolar defect; bone morphogenetic proteins; cleft lip and palate; encapsulation; liposomes